177 related articles for article (PubMed ID: 21365960)
1. MAO inhibitors.
Keller D
Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
[No Abstract] [Full Text] [Related]
2. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
3. MAO-B inhibitor know-how: back to the pharm.
Lewitt PA
Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
[No Abstract] [Full Text] [Related]
4. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
6. Rasagiline.
Schapira A; Bate G; Kirkpatrick P
Nat Rev Drug Discov; 2005 Aug; 4(8):625-6. PubMed ID: 16106586
[No Abstract] [Full Text] [Related]
7. Mao-B inhibitor know-how: back to the pharm.
Burke WJ
Neurology; 2009 Dec; 73(23):2048; author reply 2048. PubMed ID: 19996086
[No Abstract] [Full Text] [Related]
8. Reexamination of the TEMPO Study.
Shults CW
Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
[No Abstract] [Full Text] [Related]
9. MAO type B inhibitors as adjunct to L-dopa therapy.
Youdim MB; Finberg JP
Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
[No Abstract] [Full Text] [Related]
10. [The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease].
Levin OS
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(9):91-6. PubMed ID: 19004128
[No Abstract] [Full Text] [Related]
11. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
12. [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Kassubek J; Büttner T; Reichmann H; Riederer P; Schulz JB; Wüllner U; Csoti I
Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S34-6. PubMed ID: 20195940
[TBL] [Abstract][Full Text] [Related]
13. Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
Riederer P; Müller T
J Neural Transm (Vienna); 2018 Nov; 125(11):1751-1757. PubMed ID: 29569037
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
Szökő É; Tábi T; Riederer P; Vécsei L; Magyar K
J Neural Transm (Vienna); 2018 Nov; 125(11):1735-1749. PubMed ID: 29417334
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline (Azilect) for Parkinson's disease.
Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):97-9. PubMed ID: 17149358
[No Abstract] [Full Text] [Related]
16. Rasagiline as a therapy for Parkinson's disease (PD).
Hermanowicz N
Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
[No Abstract] [Full Text] [Related]
17. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Jenner P
Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
[No Abstract] [Full Text] [Related]
18. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
19. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
Naoi M; Maruyama W; Inaba-Hasegawa K
Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
[TBL] [Abstract][Full Text] [Related]
20. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
